Literature DB >> 24494792

Efficacy and mechanism of anticonvulsant drugs in migraine.

Jan Hoffmann1, Simon Akerman, Peter J Goadsby.   

Abstract

Anticonvulsants represent one of the main substance classes used for the preventive treatment of migraine. Efficacy has been demonstrated in randomized placebo-controlled trials for topiramate and valproic acid including divalproex sodium. In the case of topiramate, efficacy has recently been proven for chronic migraine and even medication overuse headache, questioning the established concept of medication withdrawal. However, preventive treatment with anticonvulsants is frequently hampered by side effects that occasionally require treatment discontinuation. In addition, these data indicate that some anticonvulsant drugs are effective in migraine, while a number are clearly not useful. Effective anticonvulsants, such as topiramate and valproate, target nociceptive trigeminovascular and trigeminothalamic dural pathways or mechanisms involved in cortical spreading depression. Dissecting out how the anticonvulsants that do not work differ mechanistically from those that do will almost certainly provide avenues through which one can develop new treatments to bring to patients with migraine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24494792     DOI: 10.1586/17512433.2014.885835

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  12 in total

Review 1.  Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update.

Authors:  János Tajti; Délia Szok; Anett Csáti; László Vécsei
Journal:  Curr Pain Headache Rep       Date:  2016-01

Review 2.  Glutamate and Its Receptors as Therapeutic Targets for Migraine.

Authors:  Jan Hoffmann; Andrew Charles
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 3.  Single-Gene Determinants of Epilepsy Comorbidity.

Authors:  Jeffrey L Noebels
Journal:  Cold Spring Harb Perspect Med       Date:  2015-11-02       Impact factor: 6.915

4.  DFT analysis of valproic acid adsorption onto Al12/B12-N12/P12 nanocages with solvent effects.

Authors:  Jamelah S Al-Otaibi; Y Sheena Mary; Y Shyma Mary
Journal:  J Mol Model       Date:  2022-03-23       Impact factor: 1.810

5.  Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety.

Authors:  Farhad Assarzadegan; Hanif Tabesh; Seyed-Mostafa Hosseini-Zijoud; Andrew David Beale; Arya Shoghli; Mahmood Ghafoori Yazdi; Behnam Mansouri; Omid Hesami; Nahid Beladi Moghadam; Hosein Delavar Kasmaei
Journal:  Iran Red Crescent Med J       Date:  2016-04-30       Impact factor: 0.611

Review 6.  Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials.

Authors:  Kai Le; Dafan Yu; Jiamin Wang; Abdoulaye Idriss Ali; Yijing Guo
Journal:  J Headache Pain       Date:  2017-07-18       Impact factor: 7.277

Review 7.  Current Status of the New Antiepileptic Drugs in Chronic Pain.

Authors:  Harpreet S Sidhu; Akshay Sadhotra
Journal:  Front Pharmacol       Date:  2016-08-25       Impact factor: 5.810

8.  The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine.

Authors:  Fenye Liu; Tianbao Ma; Xiaolin Che; Qirong Wang; Shudong Yu
Journal:  Front Neurol       Date:  2017-10-11       Impact factor: 4.003

Review 9.  Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration.

Authors:  Atsuko Kimura; Kazuhiko Namekata; Xiaoli Guo; Chikako Harada; Takayuki Harada
Journal:  Int J Mol Sci       Date:  2016-09-20       Impact factor: 5.923

10.  Topiramate modulates trigeminal pain processing in thalamo-cortical networks in humans after single dose administration.

Authors:  Julia M Hebestreit; Arne May
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.